Panzyga vs placebo in pediatric acute-onset neuropsychiatric syndrome (PANS)

Phase 3, randomised, double-blind trial of polyvalent human immunoglobulin in pediatric acute-onset neuropsychiatric syndrome (PANS) and Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) (2 arms), sponsored by Octapharma Pharmazeutika Produktionsgesellschaft mbH. Primary endpoint: Change in CY-BOCS total score from Baseline to Week 9. Started May 2024; status: completed.